JP2024517340A - アルファ－シヌクレイン凝集物を分解する化合物及びその使用 - Google Patents

アルファ－シヌクレイン凝集物を分解する化合物及びその使用 Download PDF

Info

Publication number
JP2024517340A
JP2024517340A JP2023570190A JP2023570190A JP2024517340A JP 2024517340 A JP2024517340 A JP 2024517340A JP 2023570190 A JP2023570190 A JP 2023570190A JP 2023570190 A JP2023570190 A JP 2023570190A JP 2024517340 A JP2024517340 A JP 2024517340A
Authority
JP
Japan
Prior art keywords
alkyl
formula
substituted
compound
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517340A5 (https=
Inventor
ジャン，ミン－クエイ
テンペスト，ポール
リン，イー－シャン
Original Assignee
アプリノイア セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプリノイア セラピューティクス リミテッド filed Critical アプリノイア セラピューティクス リミテッド
Publication of JP2024517340A publication Critical patent/JP2024517340A/ja
Publication of JP2024517340A5 publication Critical patent/JP2024517340A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Treating Waste Gases (AREA)
JP2023570190A 2021-05-14 2021-05-14 アルファ－シヌクレイン凝集物を分解する化合物及びその使用 Pending JP2024517340A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/054167 WO2022238737A1 (en) 2021-05-14 2021-05-14 Compounds for degrading alpha-synuclein aggregates and uses thereof

Publications (2)

Publication Number Publication Date
JP2024517340A true JP2024517340A (ja) 2024-04-19
JP2024517340A5 JP2024517340A5 (https=) 2024-05-21

Family

ID=76034924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570190A Pending JP2024517340A (ja) 2021-05-14 2021-05-14 アルファ－シヌクレイン凝集物を分解する化合物及びその使用

Country Status (8)

Country Link
EP (1) EP4337259A1 (https=)
JP (1) JP2024517340A (https=)
KR (1) KR20240008335A (https=)
CN (1) CN117377496A (https=)
AU (1) AU2021444937A1 (https=)
CA (1) CA3218573A1 (https=)
TW (1) TW202304516A (https=)
WO (1) WO2022238737A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162452A1 (zh) * 2024-01-29 2025-08-07 思努赛生物科技(上海)有限责任公司 一种识别α-突触核蛋白聚集体的化合物及其用途
CN118845735A (zh) * 2024-06-21 2024-10-29 合肥综合性国家科学中心大健康研究院 金刚烷衍生物在制备离子通道tmem175激动剂中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189566A1 (en) * 2015-12-31 2017-07-06 Washington University Alpha-synuclein ligands
WO2020264499A1 (en) * 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2021534213A (ja) * 2018-08-20 2021-12-09 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ−シヌクレインタンパク質を標的とするタンパク質分解

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
ES2965049T3 (es) 2017-07-12 2024-04-10 Dana Farber Cancer Inst Inc Compuestos para la degradación de la proteína tau
TW201946624A (zh) 2018-05-09 2019-12-16 新旭生技股份有限公司 雜芳基化合物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189566A1 (en) * 2015-12-31 2017-07-06 Washington University Alpha-synuclein ligands
JP2021534213A (ja) * 2018-08-20 2021-12-09 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ−シヌクレインタンパク質を標的とするタンパク質分解
WO2020264499A1 (en) * 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Also Published As

Publication number Publication date
CA3218573A1 (en) 2022-11-17
KR20240008335A (ko) 2024-01-18
WO2022238737A1 (en) 2022-11-17
AU2021444937A1 (en) 2023-11-30
CN117377496A (zh) 2024-01-09
TW202304516A (zh) 2023-02-01
EP4337259A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
TWI639595B (zh) 作為ＬＲＲＫ２（富含白胺酸重複激酶２）抑制劑之新穎咪唑並［４，５－ｃ］喹啉和咪唑並［４，５－ｃ］［１，５］萘啶衍生物
CN108290863B (zh) 可用作人壳多糖酶抑制剂的经取代的氨基三唑
CN115697990A (zh) 基于吲唑的化合物和相关使用方法
US11291732B1 (en) Compounds for degrading α-synuclein aggregates and uses thereof
TW201639851A (zh) 雙環咪唑衍生物
JP2019510006A (ja) グリコシダーゼ阻害剤
WO2018102751A1 (en) Ire1 small molecule inhibitors
CN110267961A (zh) Oga抑制剂化合物
JP2019532950A (ja) Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
JP2019506430A (ja) グリコシダーゼ阻害剤
CN115605267A (zh) 突变体lrrk2蛋白水解的选择性调节剂和相关使用方法
KR20150116907A (ko) 옥사디아졸 유도체, 및 대사성 글루타메이트 수용체 강화제로서의 그의 용도 - 842
JP2023532623A (ja) ハンチントン病を処置するためのｈｔｔモジュレータ
DE60305037T2 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
US20230219969A1 (en) Isotryptamine psychoplastogens and uses thereof
JP2024517340A (ja) アルファ－シヌクレイン凝集物を分解する化合物及びその使用
JP2023522078A (ja) １，５－ジヒドロ－２，４－ベンゾジアゼピン－３－オン誘導体及びその使用
RS56630B1 (sr) Fuzionisani tiazolo i oksazolo pirimidinoni
CN114450006B (zh) TrkB正别构调节剂
HK40069557B (zh) 用於降解tau蛋白聚集体的化合物及其用途
HK40069557A (en) Compounds for degrading tau protein aggregates and uses thereof
CN114073703B (zh) 用于治疗非酒精性脂肪肝炎的组合物和方法
JP2025533107A (ja) ラクテート増強化合物及びその使用
HK40080583A (en) 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof
HK40015155A (en) Monocyclic oga inhibitor compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231226

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260203